Navigation Links
Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
Date:3/21/2013

therapeutic proteins and peptides at human body temperatures for extended periods of time.

Data from Intarcia's ITCA 650 Phase 2 program have demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the GI adverse events typically associated with the self-injection products in this class. ITCA 650 is an investigational new therapy and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as twice-daily and once-weekly self-injection therapies for type 2 diabetes. Upon approval, ITCA 650 would represent the first injection-free GLP-1 therapy that can deliver a full year of treatment from a single placement. Intarcia's robust intellectual property portfolio protects ITCA 650 through 2031.

About Type 2 Diabetes

Every day, 5,225 new cases of diabetes are diagnosed in the U.S. alone, 90% to 95% of which are designated type 2 (T2D). T2D presents when the body either does not produce enough insulin or becomes resistant to insulin, resulting in high levels of blood sugar. The International Diabetes Federation estimates that 366 million adults worldwide suffered from T2D in 2011 and predicts this number will rise to 552 million by 2030; the Centers for Disease Control predicts that 25% to 33% of the U.S. adult population will have diabetes by 2050. It is estimated that pre-diabetes, or impaired glucose tolerance (IGT), a condition that often leads to diabetes, affects a population roughly twice the size of the current diabetes population. The World Health Organization estimates deaths resulting from diabetes will double between 2005 and 2030 and estimates the global cost of diabetes to have exceeded $400 billion in 2010. United Healthcare expects spending on diabetes and diabetes-related care to reach $500 billion by 2020 in the U.S. alone, and projects
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development
2. ROX Medical enrolls first UK patients in CONTROL-HTN hypertension trial at Eastbourne General Hospital
3. ROX Medical enrolls first patients in Ireland for CONTROL-HTN hypertension trial at Beaumont and Mater Private Hospitals
4. Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
5. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
6. CalHIPSO Enrolls Over 7,700 Providers in EHR Implementation Program, Hits Other Key Milestones After First Two Years
7. PQA and CECity Launch Joint Venture to Deliver First National Pharmacy Quality Measurement, Benchmarking and Reporting Platform for Pharmacies and Health Plans
8. First Patients Dosed in Proof-of-Concept Clinical Study of Alder Biopharmaceuticals Lead Therapeutic Candidate for Treatment of Migraine, ALD403
9. Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
10. Wyckoff Heights Medical Center Is First New York Hospital to Offer Asthmapolis Mobile Asthma Management Program
11. Quest Diagnostics Launches Dementia Diagnostic Panel, First in Industry for Treatable Forms of Cognitive Impairment Based on Medical Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Pharmaceutic Labs announces the opening ... Albany, NY for admixing, compounding, drug ... and/or exceeds the FDA standards for safety and quality, ... 211. The 10,000 square foot outsourcing ... quality assurance and quality control. The company will produce ...
(Date:10/19/2014)... , Oct. 20, 2014 CTI BioPharma ... it will report its third quarter 2014 financial results ... the U.S. financial markets. Following the announcement, members of ... to discuss the results and provide a general corporate ... to the event can be obtained as follows: ...
(Date:10/17/2014)... Oct. 17, 2014  Training market researchers to ... success factor in today,s highly competitive global marketplace. ... organizations that effectively and efficiently produce high performing ... area. Effective training programs can ... recognition from internal clients by developing analysts who ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2
... Genomic Health, Inc. (Nasdaq: GHDX ) today ... the following conferences in June: Brad Cole, ... 2011 Global Healthcare Conference on Monday, June 6 at 3:30 ... Genomic Health,s President and Chief Executive Officer, and Dean Schorno, ...
... announced today that it has received U.S. Food ... HypothermX™ HX100 device.  The HypothermX™ HX100 device is ... to warm intravenous fluids, blood or blood products ... trauma, environmental, procedure related, or induced hypothermia.  Heating ...
Cached Medicine Technology:Genomic Health to Present at Two Upcoming Investor Conferences 2Genomic Health to Present at Two Upcoming Investor Conferences 3EMIT Corporation Receives FDA 510(k) Clearance for HypothermX™ Blood and Fluid Warmer. 2
(Date:10/20/2014)... October 20, 2014 My Clients Plus ... software application. The new module enables easy administration ... full life-cycle quality care. , This application allows users ... their practice, attach a to-do item to a specific ... even set up reoccurring reminders for follow-ups. It's ...
(Date:10/20/2014)... October 20, 2014 Myoderm ... as Assistant Director of their CentralSource ... managing the innovative turnkey drug sourcing, distribution, and ... brings over 12 years of industry experience, in ... at the peak of their international success to ...
(Date:10/20/2014)... October 20, 2014 Based on ... the only imaging assays capable of determining DNA ... test.  With these three dimensions of high-resolution data, ... detect the widest range of disease-causing genetic rearrangements, ... by other genomic tools, including today’s advanced sequencing ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Unveiled at the ... Strategic Direction Scorecard conservatively estimates member hospital ROI on membership ... on dues, The Center provides $12.50 in value to member ... (Member Value – Member Dues)/Member Dues. , “This is ... this number and we think the methodology is really sound,” ...
(Date:10/20/2014)... October 20, 2014 Houston plastic surgeon ... the key elements of his innovative True Form ... plastic surgery residents and faculty at The University ... he, too, was once a medical student. Patronella, who ... private cosmetic plastic surgery practices in Texas, The ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... , After prenatal diagnosis with complex birth defects, hundreds ... Special Delivery Unit at The Children,s Hospital of Philadelphia ... born in 2009 in the Garbose Family Special Delivery Unit ... 2010 with their joyful families. Families from 24 states traveled ...
... , LOS ANGELES, Dec. 29 The Criminal Defense ... premier Los Angeles Fraud Defense Firm, have successfully represented numerous ... allegations of Medi-Cal and Medi-Care theft. , The ... who are facing state and federal criminal fraud charges, as ...
... RIO DE JANEIRO, Dec. 29 ... Reuters: AMIL3.SA), the,largest managed care organization in Brazil, informs its ... meeting held today, approved the,payment of Interest on Capital Stock ... to the total amount of R$ 6.0 million. The payment,will ...
... Method may cut costs, but more review is needed, researchers ... to monitor intensive care unit patients from remote locations, as ... risk of death in patients or make it more likely ... , Researchers looked at the medical records of patients in ...
... your workout routine, even in foul weather , TUESDAY, Dec. ... even the most enthusiastic exerciser,s plans. It,s hard to get ... patches. And who wants to go to the gym when ... , But sticking to your exercise program throughout the colder ...
... , TUESDAY, Dec. 29 (HealthDay News) -- Many older adults ... a new study finds that the herbal product doesn,t stave ... a big trial in older people, we didn,t see any ... age-related changes of cognition," said lead researcher Dr. Steven T. ...
Cached Medicine News:Health News:Children's Hospital Brings Hope to Special Babies and Their Families 2Health News:Children's Hospital Brings Hope to Special Babies and Their Families 3Health News:Children's Hospital Brings Hope to Special Babies and Their Families 4Health News:Los Angeles Healthcare Fraud Defense Lawyers Announce Recent Results in California Medi-Cal and Medi-Care Criminal Law Cases 2Health News:Los Angeles Healthcare Fraud Defense Lawyers Announce Recent Results in California Medi-Cal and Medi-Care Criminal Law Cases 3Health News:Amilpar - Distribution of Interest on Capital Stock 2Health News: Winter Exercise Can Lift Your Spirits 2Health News:Ginkgo Won't Slow Decline of Aging Brain 2Health News:Ginkgo Won't Slow Decline of Aging Brain 3
... Diagnostics offers Q Fever IFA Test Kits ... and IgM human antibody responses to Coxiella ... the simultaneous semi-quantitative detection and differentiation of ... Phase II antigens. By providing the two ...
Claes Shielded Retinotomy Scissors, Vertical...
... is intended for qualitatively detecting antibodies to ... The test is indicated for testing persons ... aid in the presumptive laboratory diagnosis of ... for self-testing, and this test is not ...
... test for the detection and semi-quantitation of ... Encephalitis virus (SLE), Western Equine Encephalitis virus ... California Encephalitis/La Crosse virus (CE). Each kit ... spots of SLE, WEE, EEE, and CE ...
Medicine Products: